Tracy Saxton, an alumnus of corporate venturing funds Roche Venture Fund and Pivotal BioVenture Partners, has taken an entrepreneur-in-residence (EIR) position at US-based venture capital firm Frazier Healthcare Partners.
Frazier Healthcare Partners provides VC and growth-stage funding for life sciences technology developers and has raised a total of $4.2bn since it was founded in 1991.
Saxton’s position at Frazier involves her being the founder and chief executive of Aucupo Biosciences, a stealth-stage Frazier-incubated startup developing treatments for patients suffering from conditions not sufficiently addressed by current therapies.
Prior to Frazier, Sexton co-founded Pivotal BioVenture Partners, the biotech-focused VC firm funded by property and life sciences group Nan Fung, in early 2017.
Saxton had previously spent two years as an investment director at Roche Venture Fund, the corporate venturing arm of pharmaceutical firm Roche, during which time she was named as a Global Corporate Venturing Rising Star in 2016.
The move was announced alongside Frazier’s appointment of Vanessa Bhark as senior associate. Bhark had been working on corporate development, including licenses, collaborations and acquisition deals, at biopharmaceutical company Gilead Sciences since 2014.
Jamie Topper, managing general partner of Frazier’s life sciences team, said: “We are excited to have Tracy and Vanessa join our team; collectively, they bring significant skill sets in venture, drug development and business development to the life sciences venture group.”
– Photo of Tracy Saxton courtesy of Frazier Healthcare Partners.